FAQ

GW856553

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2015
01220112015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD
BACKGROUND Corticosteroids (CS) have limited efficacy in the treatment of chronic obstructive pulmonary disease (COPD). p38… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2015
Review
2015
A randomized, placebo-controlled trial of the analgesic efficacy and safety of the p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain from lumbosacral radiculopathy.
OBJECTIVES Preclinical studies have demonstrated involvement of p38 mitogen-activated protein kinase signaling pathways in the… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2014
2014
Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre…
Pro-inflammatory cytokines (PICs) may play important pathophysiological roles in some forms of Major Depressive Disorder (MDD… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2013
2013
Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double-blind, placebo-controlled study.
BACKGROUND Inhibitors of p38 mitogen-activated protein kinase are undergoing evaluation as a novel class of anti-rheumatic drugs… (More)
Is this relevant?
2012
2012
Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.
OBJECTIVES This study sought to determine the effects of a p38 mitogen-activated protein kinase inhibitor, losmapimod, on… (More)
Is this relevant?
2012
2012
The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale.
The p38 mitogen-activated protein kinase (MAPK) is a nexus point in inflammation, sensing, and stimulating cytokine production… (More)
Is this relevant?
2011
2011
Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia.
BACKGROUND Oxidized low-density lipoprotein reduces endothelial nitric oxide production (an important mediator of vasoregulation… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?